Abstract:Encoded by PTPN11 , the Src-homology 2 domain-containing phosphatase 2 (SHP2) integrates signals from various membrane-bound receptors such as receptor tyrosine kinases (RTKs), cytokine and integrin receptors and thereby promotes cell survival and proliferation. Activating mutations in the PTPN11 gene may trigger signaling pathways leading to the development of hematological malignancies, but are rarely found in solid tumors. Yet, aberrant SHP2 expression or activation has implications in the development, progression and metastasis of many solid tumor entities. SHP2 is involved in multiple signaling cascades, including the RAS-RAF-MEK-ERK-, PI3K-AKT-, JAK-STAT- and PD-L1/PD-1- pathways. Although not mutated, activation or functional requirement of SHP2 appears to play a relevant and context-dependent dichotomous role. This mostly tumor-promoting and infrequently tumor-suppressive role exists in many cancers such as gastrointestinal tumors, pancreatic, liver and lung cancer, gynecological entities, head and neck cancers, prostate cancer, glioblastoma and melanoma. Recent studies have identified SHP2 as a potential biomarker for the prognosis of some solid tumors. Based on promising preclinical work and the advent of orally available allosteric SHP2-inhibitors early clinical trials are currently investigating SHP2-directed approaches in various solid tumors, either as a single agent or in combination regimes. We here provide a brief overview of the molecular functions of SHP2 and collate current knowledge with regard to the significance of SHP2 expression and function in different solid tumor entities, including cells in their microenvironment, immune escape and therapy resistance. In the context of the present landscape of clinical trials with allosteric SHP2-inhibitors we discuss the multitude of opportunities but also limitations of a strategy targeting this non-receptor protein tyrosine phosphatase for treatment of solid tumors.

Strategy for Leukemia Treatment Targeting SHP-1,2 and SHIP

Acute Myeloid Leukemia Cell-Intrinsic PD-1 Functions Promoting Leukemia Development by Recruiting SHP2

Roles of protein tyrosine phosphatase SHP2 in lung cancer

Targeting SHP2 As a Promising Strategy for Cancer Immunotherapy

Current Views on the Interplay between Tyrosine Kinases and Phosphatases in Chronic Myeloid Leukemia

Targeting PRL phosphatases in hematological malignancies

Targeting protein tyrosine phosphatase non-receptor type 2 with a novel inhibitor for AML therapy

SHP-1 inhibition targets leukaemia stem cells to restore immunosurveillance and enhance chemosensitivity by metabolic reprogramming

Tyrosine phosphatase PTPN11/SHP2 in solid tumors - bull's eye for targeted therapy?

From Tyrosine Kinases to Tyrosine Phosphatases: New Therapeutic Targets in Cancers and Beyond

Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders

Tyrosine phosphatase SHP2 inhibitors in tumor-targeted therapies

Overexpression Of Shp2 Tyrosine Phosphatase Is Implicated In Leukemogenesis In Adult Human Leukemia

Recent advances in the discovery of protein tyrosine phosphatase SHP2 inhibitors

Targeting Transcription Factor SALL4 in Acute Myeloid Leukemia by Interrupting Its Interaction with an Epigenetic Complex.

Targeting of phospho-eIF4E by homoharringtonine eradicates a distinct subset of human acute myeloid leukemia

Phosphatase-independent functions of SHP2 and its regulation by small molecule compounds

In vivo Targeting MEK and TNK2/SRC pathways in PTPN11 driven leukemia

Targeting Protein Tyrosine Phosphatases to Improve Cancer Immunotherapies

Functions of Shp2 in cancer

The Functional Roles of the Src Homology 2 Domain-Containing Inositol 5-Phosphatases SHIP1 and SHIP2 in the Pathogenesis of Human Diseases